Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT02310867

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Led by Linda Cendales · Updated on 2026-04-09

50

Participants Needed

1

Research Sites

691 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test. Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation. Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).

CONDITIONS

Official Title

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 to 65 years with loss of limb
  • Willingness and legal ability to give informed consent
  • Willingness to travel to study site for protocol-specific samples or ability to send samples via overnight mail
Not Eligible

You will not qualify if you...

  • Any condition preventing regular follow-up
  • Any condition that increases risk or confounds data interpretation
  • Any active malignancy or history of malignancy or lymphoma
  • Inability or unwillingness to comply with protocol monitoring, therapy, or immunodeficiency syndromes

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

Loading map...

Research Team

L

Linda Cendales, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here